Back to Awarded Treatment Trials
Awarded Trial: 03T-483
Grant ID
03T-483
Illness
Schizophrenia
Primary Drug/Intervention
D-Serine
Primary Dosage
up to 2g/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Weiser
Sample Size
200
Duration of Study Period for Each Subject
16 weeks
Outcome Measurements
PANSS, SANS, BPRS, CGI, movement disorder scales
Results
195 patients were randomized and 149 completed the trial. There were no significant differences between d-serine and controls on PANSS positive or negative symptoms or on cognitive function as assessed by the MATRICS.
Publication
D'Souza DC, Radhakrishnan R, Perry E, Bhakta S, Singh NM, Yadav R, Abi-Saab D, Pittman B, Chaturvedi SK, Sharma MP, Bell M, Andrade C. Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study. Neuropsychopharmacology. 2013 Feb;38(3):492-503.
Link
http://www.ncbi.nlm.nih.gov/pubmed/23093223
PI Name
Mark Weiser
Degree
MD
Center
Sheba Medical Center
Institution
Psychiatric Outpatient Clinic
Address
Sheba Medical Center
City or Town
Tel Hashomer
State or Province
N/A
Zip or Postal Code
52621
Country
Israel
Email Address
mweiser@netvision.net.il